Satisfying Aggressive Timelines With a Simplified Supply Chain for Drug Delivery

Designed specifically for new and emerging companies such as Kaleido Biosciences, The Quick to Care™ program is an integrated solution that combines drug substance and drug product development, clinical manufacturing, forecasting, demand planning and clinical trial supply execution managed by a single program manager.

Download this brochure to learn how Kaleido Biosciences was able to simplify their supply chain to meet their aggressive timeline with the Quick to Care™ program.

Kaleido Biosciences Successfully Meets Aggressive IND Filing Date Thanks to Strategic Partnership

Cost Savings and Speed from a Single-Source Solution

In small pharmaceutical start-ups, you have to move fast with a limited amount of budget and resources to get your molecule to first-in-human, and then to proof-of-concept (POC). You keep headcount low and outsource wherever you can, often to multiple vendors. Working with multiple vendors means investing significant time to negotiate terms and conditions as well as to oversee the project.

PSG Global Site Network Map

Learn more about our fully integrated global site network that can support your molecule from development to commercialization.

The Economic Advantage of Single-Source Drug Development and Manufacturing

Tufts Center for the Study of Drug Development (CSDD) recently completed research, titled “Assessing the Economics of Single-Source vs. Multi-Vendor Manufacturing” that compared cycle times and development economics between multi- and single-source CDMO models. While there are many studies that debate the total cost of drug development,1-3 the Tufts study sought a better understanding of which model offered the most accelerated time-to-market for its clients. By focusing on time as a primary value driver, a sponsor can lower the overall cost of bringing its drug to market, and more importantly, achieve the speed-to-market patients both want and need.

Quick to Care™ Fact Sheet

Take months off the development timelines of your large and small molecule discoveries. With Quick to Care™ you can combine your drug substance and drug product development, demand planning and clinical trial supply execution into a single customized solution to simplify your supply chain and accelerate your discovery through clinical development. You’ll be able to develop small molecules 8–12 weeks faster than the industry-standard 15 months, and large molecules 14–20 weeks faster. And the advantages don’t end there…

Tightening The Supply Chain: Patheon Aims to Transform Pharma Outsource Manufacturing

Opportunities to transform an industry are rare, but often they develop from unexpected sources. Long considered an essential yet largely commodity-output business, biopharmaceutical supply chain management may emerge as a hidden transformational force for the industry.